TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
TAS-120 overcomes resistance to ATP-Competitive FGFR inhibitors in patients with FGFR2 fusion-possible intrahepatic cholangiocarcinoma.